Alvotech and Advanz link-up for Xolair drive
Alvotech will be responsible for supply and Advanz will oversee commercialisation of biosimilar
Read More
Tag: Xolair
Roche’s Xolair gets US nod for nasal polyps treatment
IgE blocker approved as an add-on treatment for adult patients
Read More
FDA accepts application for self-administered Xolair use
If approved drug would offer a more flexible option for patients
Read More
EU approves new indication for Novartis’ Xolair
Allergy drug approved for severe chronic rhinosinusitis with nasal polyps
Read More
Ligelizumab continues to trump Xolair in chronic spontaneous urticaria
The Novartis drug can bind to IgE with an 88-fold higher affinity than Xolair.
Read More
Ligelizumab trumps Xolair in spontaneous urticarial trial
The drug achieved complete control of hives in 51% and 42% of patients, compared with 26% of patients treated with Xolair.
Read More
Xolair deemed ‘breakthrough’ therapy for food allergies
Roche/Novartis’ Xolair has been awarded breakthrough status in the US for treatment of severe allergic reactions after accidental exposure to foods allergens.
Read More
Novartis’ Xolair backed in global urticaria guidelines
Novartis’ Xolair has been recommended in global guidelines for treating chronic spontaneous urticaria in patients unresponsive to antihistamines.
Read More
GSK’s Nucala improves control of severe asthma
GlaxoSmithKline has presented data showing that its biologic Nucala improved asthma control in patients with severe disease not adequately managed with Novartis’ Xolair.
Read More
FDA expands use of Novartis/Genentech’s asthma drug
US regulators have approved an expanded age range for Novartis/Genentech’s Xolair, giving younger children with moderate to severe persistent asthma a new option to help control their disease.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
